Stock Track | West Pharmaceutical Soars 5.90% in Pre-Market on Strong Q4 Earnings Beat and Positive Guidance

Stock Track

Feb 12

West Pharmaceutical Services Inc. (WST) saw its stock price soar 5.90% during pre-market trading on Thursday, following the release of its fourth-quarter and full-year 2025 financial results.

The significant price movement was driven by the company reporting better-than-expected quarterly performance. West Pharmaceutical posted Q4 adjusted diluted earnings per share (EPS) of $2.04, surpassing the IBES estimate of $1.83. Furthermore, Q4 net sales reached $805 million, exceeding the estimated $794.4 million. The adjusted diluted EPS represented a 12.1% increase year-over-year, highlighting strong operational performance.

Additionally, the company provided optimistic financial guidance for fiscal year 2026, including an outlook for adjusted EPS in the range of $7.85 to $8.20 and net sales between $3,215 million and $3,275 million. The positive results and forward-looking statements have bolstered investor confidence, leading to the pre-market surge.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1170368695"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1170368695\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1170368695?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-12 19:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1170368695","market":"nz","top_or_hot":-1,"title":"Stock Track | West Pharmaceutical Soars 5.90% in Pre-Market on Strong Q4 Earnings Beat and Positive Guidance","media":"Stock Track","content":"<p>West Pharmaceutical Services Inc. (WST) saw its stock price soar 5.90% during pre-market trading on Thursday, following the release of its fourth-quarter and full-year 2025 financial results.</p><p>The significant price movement was driven by the company reporting better-than-expected quarterly performance. West Pharmaceutical posted Q4 adjusted diluted earnings per share (EPS) of $2.04, surpassing the IBES estimate of $1.83. Furthermore, Q4 net sales reached $805 million, exceeding the estimated $794.4 million. The adjusted diluted EPS represented a 12.1% increase year-over-year, highlighting strong operational performance.</p><p>Additionally, the company provided optimistic financial guidance for fiscal year 2026, including an outlook for adjusted EPS in the range of $7.85 to $8.20 and net sales between $3,215 million and $3,275 million. The positive results and forward-looking statements have bolstered investor confidence, leading to the pre-market surge.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | West Pharmaceutical Soars 5.90% in Pre-Market on Strong Q4 Earnings Beat and Positive Guidance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | West Pharmaceutical Soars 5.90% in Pre-Market on Strong Q4 Earnings Beat and Positive Guidance\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-02-12 19:06</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>West Pharmaceutical Services Inc. (WST) saw its stock price soar 5.90% during pre-market trading on Thursday, following the release of its fourth-quarter and full-year 2025 financial results.</p><p>The significant price movement was driven by the company reporting better-than-expected quarterly performance. West Pharmaceutical posted Q4 adjusted diluted earnings per share (EPS) of $2.04, surpassing the IBES estimate of $1.83. Furthermore, Q4 net sales reached $805 million, exceeding the estimated $794.4 million. The adjusted diluted EPS represented a 12.1% increase year-over-year, highlighting strong operational performance.</p><p>Additionally, the company provided optimistic financial guidance for fiscal year 2026, including an outlook for adjusted EPS in the range of $7.85 to $8.20 and net sales between $3,215 million and $3,275 million. The positive results and forward-looking statements have bolstered investor confidence, leading to the pre-market surge.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"WST","symbol_name":"West Pharmaceutical Services Inc","start_time":0,"source_url":"","article_id":"1170368695","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1170368695","pubTimestamp":1770894409,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"West Pharmaceutical Services Inc. (WST) saw its stock price soar 5.90% during pre-market trading on Thursday, following the release of its fourth-quarter and full-year 2025 financial results.The...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"WST":"West Pharmaceutical Services Inc"},"translate_title":"个股赛道|西部药业盘前大涨5.90%因Q4盈利强劲超预期及正面指引","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"WST":1},"content_text":"West Pharmaceutical Services Inc. (WST) saw its stock price soar 5.90% during pre-market trading on Thursday, following the release of its fourth-quarter and full-year 2025 financial results.The significant price movement was driven by the company reporting better-than-expected quarterly performance. West Pharmaceutical posted Q4 adjusted diluted earnings per share (EPS) of $2.04, surpassing the IBES estimate of $1.83. Furthermore, Q4 net sales reached $805 million, exceeding the estimated $794.4 million. The adjusted diluted EPS represented a 12.1% increase year-over-year, highlighting strong operational performance.Additionally, the company provided optimistic financial guidance for fiscal year 2026, including an outlook for adjusted EPS in the range of $7.85 to $8.20 and net sales between $3,215 million and $3,275 million. The positive results and forward-looking statements have bolstered investor confidence, leading to the pre-market surge.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}